In a report released on January 27, Naz Rahman from Maxim Group reiterated a Buy rating on Silexion Therapeutics (SLXN – Research Report), with ...

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi ...

Silexion Therapeutics Corp. (NASDAQ:SLXN) released new preclinical data for SIL-204, its next-generation siRNA therapeutic ...

Three nano-cap healthcare stocks drew massive attention from retail investors on Stocktwits Tuesday, though not all for ...

It expects to announce details of its expanded development plan shortly. Price Action: SLXN stock is up 130.2% at $1.33 at last check Tuesday.

In a remarkable display of market confidence, Moringa Acquisition Corp (MACA) stock has reached an all-time high, touching a price level of $13.56. This peak represents a... ByInvesting.com ...

In a challenging year for Moringa Acquisition Corp (SLXN), the company's stock has plummeted to a 52-week low, trading at $0.79, with a market capitalization of just $1.29 million. InvestingPro ...

Cayman Islands, January 29, 2025 -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech ...

(RTTNews) - Silexion Therapeutics Corp. (SLXN), a clinical-stage biotechnology company, announced Tuesday significant preclinical data for SIL-204, its next-generation siRNA therapeutic candidate ...